A licence with India's OneSource shows how Saudi drugmakers are positioning for the tirzepatide patent cliff, and what launch and market access teams should research now.
Saudi drugmaker Avalon Pharma has signed an exclusive licence to register and sell a generic version of Eli Lilly's Mounjaro KwikPen in Saudi Arabia and other Middle East and North Africa (MENA) markets, according to its filing on the Saudi Exchange (Tadawul). The partner is OneSource Specialty Pharma, an Indian contract developer and manufacturer.
The medicine is tirzepatide, the active ingredient in Mounjaro. It is one of the newer injectable drugs for type 2 diabetes and weight management that act on GLP-1, a gut hormone that lowers blood sugar and reduces appetite. Tirzepatide also acts on a second hormone receptor, GIP, which is why it is often called a "dual agonist".
The catch is timing. Avalon says the product will launch in each market only after the relevant patents expire, both in the launch market and in the country of manufacture. Neither company has published those dates. So this is a deal signed today for a market that does not yet exist.
A note on sources. The deal terms come from Avalon Pharma's Tadawul disclosure (published 11 October 2026) and from Argaam and Mubasher reports of it. Dawaa News MENA, which surfaced the story on LinkedIn on 4 November 2026, described the product only as an injectable for weight management and did not name it. OneSource's corporate facts come from its own exchange filing of 11 February 2026. Patent dates come from Eli Lilly's 2025 annual report (Form 10-K). Prevalence figures come from the IDF Diabetes Atlas 11th edition and the Saudi General Authority for Statistics (GASTAT). Where the record is silent, we say so.
How Dawaa News surfaced the story
Dawaa News MENA posted the item on its LinkedIn company page under the Arabic headline "أفالون فارما تبرم شراكة دولية مع شركة OneSource للتوسع في أدوية السمنة والأمراض الأيضية بالسعودية وأسواق المنطقة". In English: "Avalon Pharma signs an international partnership with OneSource to expand in obesity and metabolic medicines in Saudi Arabia and regional markets." The post links to a full Dawaa News article dated 4 November 2026.
The Dawaa piece frames the deal around weight management, sterile manufacturing and a future technology transfer clause. It does not name the molecule. That detail is in the Tadawul filing, which Avalon published almost four weeks earlier.
For BioNixus, Dawaa News is an alert layer. We use it to spot a story, then go to the primary filing. Here the filing changes the story. "An injectable for weight management" could mean many things. "A generic of Mounjaro KwikPen in six strengths" means one specific and very large product.
What Avalon actually signed
The Tadawul disclosure is short and specific. Here is what it says, in plain terms:
- Who: Middle East Pharmaceutical Industries Co., which trades as Avalon Pharma, signed with OneSource Specialty Pharma Limited, a company incorporated in India.
- When: The contract was signed on 8 October 2026. The disclosure was posted on Tadawul on 11 October 2026.
- What: An exclusive licence to OneSource's registration dossier for a tirzepatide multi-dose pen in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg strengths. Avalon describes it as a generic of Mounjaro KwikPen.
- Where: Saudi Arabia and other MENA markets. Avalon will be the marketing authorisation holder, meaning the company legally responsible for the product with each regulator.
- Technology transfer: Avalon has the right to request transfer of the manufacturing technology after the commercial launch.
- Term: 10 years from launch, then automatic one-year renewals.
- Value: The contract value is less than 5% of Avalon's revenue for 2025. Argaam reports that revenue at about SAR 460.5 million, which puts the 5% line at about SAR 23 million.
- Expected revenue: Avalon expects the contract to generate cumulative revenue of not less than SAR 800 million in the first five years after launch.
- Launch timing: Each market launches only after the relevant patents expire in that market and in the country of manufacture.
Two numbers in that list deserve a second look. The contract itself is small relative to Avalon's revenue. The revenue Avalon expects from it is not. A simple average of SAR 800 million over five years is SAR 160 million a year. That is roughly a third of Avalon's entire 2025 revenue, on Argaam's figure. That calculation is ours, not Avalon's, and the company has not said how the SAR 800 million would be split by year or by country.
Who is OneSource, and why it already matters in Saudi Arabia
OneSource Specialty Pharma is listed in India (BSE: 544292, NSE: ONESOURCE) and was formerly called Stelis Biopharma. In its own words, it is a "pure-play specialty pharmaceutical CDMO", a contract development and manufacturing organisation that makes products for other drug companies. It lists biologics, drug-device combinations, sterile injectables and soft gelatine capsules among its capabilities. It says it has five manufacturing facilities and more than 1,600 staff.
This is not OneSource's first Saudi GLP-1 move. On 11 February 2026, the company told Indian exchanges that it had received Saudi Food and Drug Authority (SFDA) approval for its generic version of Ozempic (semaglutide). Its exclusive commercialisation partner for MENA on that product is Hikma Pharmaceuticals. OneSource said it would manufacture the semaglutide at its biologics and drug-device combination facility in Bengaluru.
Put the two deals side by side and a pattern appears. One Indian manufacturer now has a generic semaglutide partner and a generic tirzepatide partner for the Saudi market. They are different Saudi-facing partners for different molecules. For anyone watching the GLP-1 class in the Gulf, that is a signal that the generic supply side is organising early.
At the time of writing we could not find a OneSource exchange filing or press release about the Avalon deal. The deal terms in this article therefore rest on Avalon's side of the disclosure.
Who is Avalon Pharma
Avalon Pharma was founded in 1998 and is based in Riyadh, according to Dawaa News. Its shares trade on Tadawul's main market under the symbol 4016. Dawaa reports that it listed in January 2024 and exports to more than ten countries in the Middle East and North Africa.
The company is led by Mohamed Maher Al Ghannam, Managing Director and CEO. Avalon's own newsroom, its 2024 annual report and Forbes Middle East all give him that title. Forbes Middle East reports that he joined Avalon in 2000 and has been CEO since 2018. Fayez Awadeh is listed as Chief Marketing Officer in Avalon's 2024 annual report. Both were tagged in the Dawaa News LinkedIn post.
Tirzepatide is not Avalon's first obesity deal. On 4 August 2025, Avalon announced an agreement with Adalvo, a Malta-based pharmaceutical company, for exclusive rights to register, market and distribute Adalvo's GLP-1 products for chronic obesity and weight loss in selected MENA markets, including Saudi Arabia. Avalon said that deal ran for seven years, carried an initial fee of EUR 3 million, and included provisions for more GLP products and possible local manufacturing. It did not name the molecules.
Two days before the OneSource signing, on 6 October 2026, Avalon also disclosed a non-binding memorandum of understanding with China's Aurisco Pharma on oligonucleotides and other complex products. The first identified project is inclisiran, a cholesterol-lowering injection. That memorandum gives the parties six months to agree a term sheet and mentions local manufacturing in Riyadh.
The direction is clear. Avalon is building a portfolio of complex injectables through licences, and it is writing technology transfer options into the contracts.
Why tirzepatide is the prize
Tirzepatide is one of the best-selling medicines in the world. Eli Lilly's 2025 Form 10-K reports Mounjaro revenue of USD 22.97 billion for 2025, up from USD 11.54 billion in 2024. Of that, USD 9.32 billion came from outside the United States. Zepbound, the same molecule branded for obesity in the US, Canada and Japan, added USD 13.54 billion.
A generic version therefore aims at a very large and still growing category. But nobody can sell a generic until the protection runs out. Lilly's 10-K estimates the compound patent for Mounjaro and Zepbound expires in 2036 in the US, 2037 in major European countries and 2040 in Japan. Lilly lists data protection expiry as 2027 in the US, 2033 in major European countries and 2030 in Japan.
Lilly does not publish Saudi or Indian dates in that table, and Avalon has not disclosed them. Patent status can differ widely by country. In some markets the compound patent may not exist or may be challenged. In others, secondary patents on the pen or formulation may matter. That is exactly why the Avalon clause ties launch to expiry "both in launch market and in the country of manufacture". OneSource makes products in India. If the Indian patent position blocks manufacture, an open Saudi market does not help.
My take: the most important unknown in this deal is not the price or the partner. It is the patent map. Until someone publishes credible Saudi, GCC and Indian expiry dates for tirzepatide, every launch forecast for a generic is a scenario, not a plan.
The size of the Saudi metabolic problem
The demand case for GLP-1 medicines in Saudi Arabia does not need exaggeration. The official numbers are large enough.
Obesity. GASTAT's Health Determinants Statistics publication for 2024 reports that 23.1% of Saudi adults aged 15 and over are obese, meaning a body mass index (BMI) of 30 or more. A further 45.1% are classified as overweight. Among children and adolescents aged 2 to 14, obesity prevalence is 14.6% and overweight is 33.3%. These figures come from the National Health Survey and are based on self-reported height and weight, which tends to understate true BMI.
Diabetes. The IDF Diabetes Atlas 11th edition (2025) estimates that 5.34 million adults aged 20 to 79 in Saudi Arabia had diabetes in 2024. The age-standardised prevalence is 23.1%. IDF estimates that 43.6% of adults with diabetes in the Kingdom are undiagnosed, and projects 9.5 million Saudi adults with diabetes by 2050.
Yes, both headline percentages are 23.1%. They measure different things in different age groups, and the match is a coincidence. Teams should not merge them into one "metabolic" figure.
The region. IDF counts 84.7 million adults with diabetes across its Middle East and North Africa region in 2024, rising to a projected 162.6 million by 2050. Among the top five countries in that region for age-standardised prevalence, IDF lists Kuwait (25.6%), Qatar (24.6%), Saudi Arabia (23.1%) and Egypt (22.4%).
Prevalence is not demand. Not every adult with obesity is eligible for a GLP-1 medicine, wants one, or can pay for one. But these numbers explain why companies are signing for products years ahead of launch.
Localisation: what technology transfer can and cannot mean
The clause that gives Avalon the right to request technology transfer after launch is the one most likely to be quoted in Saudi coverage. Avalon itself links the deal to Saudi Vision 2030, and Dawaa News connects the clause to the National Industrial Development and Logistics Program (NIDLP) and its aim of localising pharmaceutical manufacturing.
It is worth being precise about what the filing says. Avalon has the right to request the transfer. The filing does not say the transfer will happen, when it would happen, which steps would move (filling, finishing, device assembly or active ingredient), or who would pay. Dawaa News makes the same point: OneSource's broad capabilities do not automatically fall within the scope of this agreement.
The sequence is also notable. The product launches first, imported. Local manufacture, if any, comes after. That is a common model for complex injectables in the Gulf, and it matters for market access. A company that can later say "made in Saudi Arabia" may gain an advantage in public tenders and with stakeholders who prioritise supply security. A company that cannot may compete harder on price.
For research teams, this creates a question worth testing early. How much do Saudi payers, procurement bodies and physicians actually value local manufacture for a chronic injectable? Is it a tie-breaker, a requirement, or a nice story? The answer will differ between government hospitals, private insurers and cash-pay clinics.
What generic GLP-1 entry could look like in Saudi Arabia
Saudi Arabia is already seeing the first wave of GLP-1 generics. OneSource and Hikma announced SFDA approval of a generic semaglutide in February 2026. Tirzepatide would be a second wave, later and dependent on patents.
Several things about that second wave are still open:
- Indications. SFDA will decide what any generic tirzepatide is approved for. The originator in some markets carries separate brands for diabetes and for obesity. Dawaa News notes that each regulator sets the approved indications. A generic launched only for type 2 diabetes would reach a different patient pool than one also approved for weight management.
- Device and dosing. The licence covers a multi-dose pen in six strengths. Pen usability, needle supply, storage and patient training will shape real-world uptake as much as price.
- Price. No price has been disclosed. A registered price would follow SFDA's pricing process, and any public tender price would be set through procurement. We have not assumed a discount.
- Channel. Obesity treatment is often paid for differently from diabetes treatment, and coverage varies by payer. Generic entry may reach cash-pay patients first, and insurers or public payers later, if at all for obesity. This is a question to test, not an assumption.
- Competition. By the time tirzepatide generics can launch, the class may include more oral and injectable options. A generic of one of today's leading products will compete with tomorrow's new brands, not only with today's originator.
What launch and market access teams should research now
If you work on GLP-1, obesity or diabetes products in Saudi Arabia or the wider GCC, this deal is a reason to start some research earlier than you might expect. Here is where we would begin.
1. Map the patent and exclusivity scenarios. Work with legal and IP teams to build credible early, base and late scenarios for tirzepatide generic entry in Saudi Arabia, the UAE, Kuwait, Egypt and India. Every downstream forecast depends on this.
2. Measure physician readiness for generic GLP-1s. Survey endocrinologists, internists, family physicians and bariatric surgeons. Ask how they would choose between an originator and a generic GLP-1, what would make them switch a stable patient, and how much device familiarity matters. Our GLP-1 physician survey in Saudi Arabia shows how we approach this.
3. Understand the payer and procurement view. Interview payers, hospital formulary committees and procurement stakeholders. Test how obesity coverage might change with lower-cost generics, and how local manufacture is weighed. See our NUPCO tendering guide for the public procurement context.
4. Size the real treatable population. Move from prevalence to eligibility, then to diagnosis, prescription, persistence and payment. The 43.6% undiagnosed diabetes figure alone shows how wide the gap can be between disease burden and treated patients.
5. Listen to patients and pharmacists. Ask people living with obesity what they pay today, where they buy, how long they stay on treatment and why they stop. Ask pharmacists what they see at the counter. These answers will shape the case for a generic more than any headline number.
6. Plan the registration path. Generic injectables with a device component have specific dossier demands. Our SFDA drug registration guide covers the basics.
Who wins, who loses, and what sceptics would say
Possible winners. Patients and payers, if generics eventually lower the cost of a widely used class. Avalon, if its early dossier access gives it a head start on day one of each market's opening. OneSource, which gains a second Saudi-market GLP-1 route.
Possible losers. Originators face eventual price pressure, though not soon on the patent dates Lilly publishes for major markets. Late-moving generic companies may find the best regional partners already signed.
The sceptic's case. The revenue expectation of SAR 800 million over five years rests on a launch date nobody has published, a price nobody has set, and an indication nobody has approved. Licences signed far ahead of patent expiry can be overtaken by litigation, new patents, new competitors or changes in clinical practice. A sceptic would also note that the right to request technology transfer is not the same as a commitment to localise.
Both views can be true. The deal is a credible bet on a very large category. It is also a long-dated bet, and its value depends on facts that are not yet public.
What to watch next
- Patent signals. Any public information on tirzepatide patent expiry or challenges in Saudi Arabia, the GCC or India.
- SFDA filings and approvals. Whether Avalon submits a dossier, and what indications SFDA approves for any generic tirzepatide.
- OneSource disclosures. Whether OneSource confirms the Avalon deal in an Indian exchange filing, and whether it signs other MENA tirzepatide partners outside Avalon's territories.
- Avalon's next steps. Whether the Adalvo GLP-1 products are named or registered, and whether the Aurisco memorandum becomes a binding agreement within its six-month window.
- Semaglutide generics. How quickly generic semaglutide gains share in Saudi Arabia after the February 2026 approval. That will be the best real-world preview of what tirzepatide generics may face.
How BioNixus helps
BioNixus has run healthcare and B2B market research since 2012, with 118 clients in 48 countries. Our physician network is 82,000+ physicians globally and about 3,200 in the Middle East. Mohammad Alsaadany, our AMEA Director, leads our work across APAC, the Middle East and Africa. We work from our Americas office and global HQ in the USA, our Europe office in the UK, our AMEA office in Cairo and our KSA partner office in Al Khobar.
For GLP-1, obesity and diabetes teams in Saudi Arabia and the GCC, we run:
- Physician research with endocrinologists, internists, family physicians and bariatric surgeons, through physician insights studies, surveys and in-depth interviews.
- Payer, formulary and procurement interviews on coverage, tender criteria and the weight given to local manufacture.
- Patient and pharmacist research in Arabic and English on cost, persistence, channel and device experience.
- Demand and patient-flow models that move from prevalence to treated patients under different generic entry scenarios.
- GCC comparisons across Saudi Arabia, the UAE, Kuwait, Qatar, Bahrain and Oman.
Read more about our GCC obesity market work and our healthcare market research in Saudi Arabia. For a related Saudi diabetes story, see our analysis of EVA Pharma's TriGutirek XR launch.
Plan your Saudi GLP-1 and obesity research with BioNixus
If you are planning for generic GLP-1 entry in Saudi Arabia or the GCC, start with the physicians, payers and patients who will decide uptake. Visit bionixus.com or contact our team to scope a study.
This article summarises public company disclosures, regulatory information and published statistics. It is not medical, legal, investment or regulatory advice, and it does not recommend any medicine. Product use in Saudi Arabia is governed by SFDA-approved product information.
